Moderna Inc (MRNA)
53.54
-1.09
(-2.00%)
USD |
NASDAQ |
Nov 04, 16:00
53.60
+0.06
(+0.11%)
After-Hours: 05:51
Moderna Research and Development Expense (Annual): 4.845B for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 4.845B |
| December 31, 2022 | 3.295B |
| December 31, 2021 | 1.991B |
| December 31, 2020 | 1.37B |
| Date | Value |
|---|---|
| December 31, 2019 | 496.00M |
| December 31, 2018 | 454.08M |
| December 31, 2017 | 410.46M |
| December 31, 2016 | 274.72M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
496.00M
Minimum
2019
4.845B
Maximum
2023
2.399B
Average
1.991B
Median
2021
Research and Development Expense (Annual) Benchmarks
| Eli Lilly and Co | 9.313B |
| Merck & Co Inc | 30.53B |
| Pfizer Inc | 10.68B |
| Novavax Inc | 737.50M |
| Amgen Inc | 4.784B |